Found: 16
Select item for more details and to access through your institution.
Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1393191
- By:
- Publication type:
- Article
Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.768592
- By:
- Publication type:
- Article
Bioactive Lipids as Chronic Myeloid Leukemia's Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.840173
- By:
- Publication type:
- Article
Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 1, p. 206, doi. 10.1111/bjh.19107
- By:
- Publication type:
- Article
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 2, p. 438, doi. 10.1007/s10637-021-01197-0
- By:
- Publication type:
- Article
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 3, p. 736, doi. 10.1007/s10637-020-01028-8
- By:
- Publication type:
- Article
Differential cytokine network profile in polycythemia vera and secondary polycythemia.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-63680-7
- By:
- Publication type:
- Article
Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.665037
- By:
- Publication type:
- Article
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression.
- Published in:
- Science Translational Medicine, 2016, v. 8, n. 350, p. 1, doi. 10.1126/scitranslmed.aad6066
- By:
- Publication type:
- Article
Metformin exerts multitarget antileukemia activity in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasms.
- Published in:
- Cell Death & Disease, 2018, v. 9, n. 3, p. 1, doi. 10.1038/s41419-017-0256-4
- By:
- Publication type:
- Article
DNMT1-interacting RNAs block gene-specific DNA methylation.
- Published in:
- Nature, 2013, v. 503, n. 7476, p. 371, doi. 10.1038/nature12598
- By:
- Publication type:
- Article
The co-expression ofPML/RARα andAML1/ETOfusion genes is associated with ATRA resistance.
- Published in:
- 2005
- By:
- Publication type:
- Book Review
Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
- Published in:
- Cancer Science, 2022, v. 113, n. 2, p. 597, doi. 10.1111/cas.15210
- By:
- Publication type:
- Article
Philadelphia-negative myeloproliferative neoplasms display alterations in monocyte subpopulations frequency and immunophenotype.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms.
- Published in:
- Medical Oncology, 2022, v. 39, n. 8, p. 1, doi. 10.1007/s12032-022-01696-x
- By:
- Publication type:
- Article
Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms.
- Published in:
- 2022
- By:
- Publication type:
- journal article